Skip to main navigationSkip to News Headlines
NJ Division of Consumer Affairs
Global Navigation
Division of Consumer Affairs
The State of New Jersey Office of The Attorney General (Dept. of Law & Public Safety) The State of New Jersey NJ Home Services A to Z Departments/Agencies OAG Frequently Asked Questions
OAG Home
OAG Contact
Division of Consumer Affairs Alerts and Recalls
Division of Consumer Affairs Alerts and Recalls
Office of the Attorney General Homepage Division of Consumer Affairs, Director
Division of Consumer Affairs, Director
Division of Alcoholic Beverage Control
Division of Consumer Affairs
Division of Consumer Affairs Highlights
Division of Consumer Affairs Topics in a A-Z List Format
Office of Consumer Protection (OCP)
New Jersey Bureau of Securities
Office of Weights and Measures
Legalized Games of Chance Control Commission
Alternative Dispute Resolution
Professions and Occupations List
Contact the Division of Consumer Affairs
Division of Consumer Affairs in Spanish
Division of Criminal Justice
Division on Civil Rights
Division of Gaming Enforcement
Division of Highway Traffic Safety
Division of Law
Juvenile Justice Commission
NJ Racing Commission
State Athletic Control Board
Division of NJ State Police
Victims of Crime Compensation Office
OPRA - Open Public Records Act
Download Free PDF Reader

spacer spacer spacer
For Immediate Release: For Further Information:
May 22, 2014

Office of The Attorney General
John J. Hoffman, Acting Attorney General

Division of Consumer Affairs
Steve C. Lee, Acting Director

Division of Law
Jeffrey S. Jacobson, Director
Media Inquiries
Jeff Lamm or
Neal Buccino
spacer spacer spacer
New Jersey Prescription Monitoring Program Now Sharing Data with Connecticut, Giving Healthcare Practitioners in Both States Even Greater Power to Fight Prescription Drug Abuse
spacer spacer spacer
NEWARK – The New Jersey Prescription Monitoring Program (NJPMP) is now actively sharing data with Connecticut's Prescription Monitoring Program in a partnership to empower New Jersey's licensed healthcare professionals in the fight against prescription drug abuse and diversion, Acting Attorney General John J. Hoffman announced today.

"The NJPMP is not just a statewide resource, but a regional resource to fight the epidemic of opiate abuse," Acting Attorney General Hoffman said.  "As powerful as our prescription tracking database is, healthcare users were only able to obtain information about prescriptions written in New Jersey. Today we are expanding the NJPMP to help prescribers and pharmacists identify doctor-shopping and other suspicious behaviors across state lines."

The partnership with Connecticut is just the beginning, Acting Attorney General Hoffman noted. The New Jersey Division of Consumer Affairs, which maintains the NJPMP, also is working to implement a partnership with the State of Delaware for mutual data-sharing between the two states' prescription monitoring programs. The Division also is communicating with other states, with the ultimate goal of creating a regional Prescription Monitoring Program network. The National Association of Boards of Pharmacy (NABP) is facilitating the connection between New Jersey's and Connecticut's prescription monitoring programs, through its PMP Interconnect (PMPi) data-sharing hub. 

"Our goal is to make New Jersey's Prescription Monitoring Program a model for the nation in terms of its ease of use, breadth of available data, and usage by prescribers and pharmacists," Division of Consumer Affairs Acting Director Steve Lee said. "The Division of Consumer Affairs doesn't just regulate the healthcare community; we are working to fully engage that community in the fight against this public health crisis."

The NJPMP collects detailed information on every prescription filled in New Jersey for controlled dangerous substances (CDS) or human growth hormone – more than 32 million prescriptions since data collection began in September 2011.  Each record includes the names of the patient, doctor, and pharmacy; purchase date; type, dosage and amount of medication; and method of payment. 

The NJPMP is available to all licensed healthcare practitioners who are authorized by the State of New Jersey to prescribe or dispense CDS medications.  They can search individual patients' prescribing patterns and learn, for example, whether a patient has engaged in "doctor shopping" – deceptively visiting multiple physicians, to obtain more narcotics than any one doctor would prescribe – or other patterns consistent with addiction or abuse.

Through the new partnership between the New Jersey Division of Consumer Affairs and the Connecticut Department of Consumer Protection, licensed healthcare practitioners in each state now are able to access data from the other state's prescription monitoring program.

Each state's requirements for, and limitations on, prescription monitoring program data will remain in place under the data-sharing agreements. For example, New Jersey healthcare practitioners who wish to access data from Connecticut's prescription monitoring program must be properly licensed and registered in New Jersey, and must meet all applicable requirements of Connecticut's prescription monitoring program.  Practitioners licensed in Connecticut are similarly bound by New Jersey's requirements regarding access to, and confidentiality of, NJPMP data.

"The ability to share controlled substance prescription data across our two states will be of great help in properly managing patient treatment, including referrals to substance abuse or addiction treatment when appropriate," Connecticut Commissioner of Consumer Protection William M. Rubenstein said. "The scourge of prescription drug abuse defies geographical boundaries as it disregards human lives."

Today's announcement was made in connection with National Prevention Week, an observance dedicated to increasing public awareness of substance abuse issues.

On Tuesday, the Star-Ledger published an op-ed by Acting Director Lee, urging New Jersey's licensed healthcare providers to embrace the NJPMP as a life-saving tool in the fight against prescription drug abuse.  The op-ed can be read in full here.

For much more information on the New Jersey Division of Consumer Affairs' initiative to halt the diversion and abuse of prescription drugs, view the Division's NJPMP website, and the Division's Project Medicine Drop website.

Follow the Division of Consumer Affairs on Facebook, and check our online calendar of upcoming Consumer Outreach events.


Contact Us | Privacy Notice | Legal Statement | Accessibility Statement
NJ Home Logo
Divisional: DCA Home | Complaint Forms | Proposals | Adoptions | Contact DCA
Departmental: OAG Home | Contact OAG | About OAG | OAG News | OAG FAQs
Statewide: NJ Home | Services A to Z | Departments/Agencies | FAQs
Copyright State of New Jersey
This page is maintained by DCA. Comments/Questions: email

Page last modified: